US stock futures flounder amid tech weakness, Fed caution
Evolent Health Inc . (NYSE:EVH) stock has experienced a significant downturn, touching a 52-week low of $9.44. According to InvestingPro data, the company maintains a market capitalization of $1.1 billion despite the decline, with analysis suggesting the stock may be undervalued at current levels. This latest price level reflects a stark contrast to the company’s performance over the past year, with Evolent Health witnessing a precipitous 1-year change of -72.13%. While the company faces profitability challenges with a current ratio of 0.85, it has demonstrated strong revenue growth of 30% over the last twelve months. The decline to this year’s low point underscores the challenges faced by the healthcare company in a volatile market environment, as investors react to a complex mix of industry-specific headwinds and broader economic pressures. The substantial drop in Evolent Health’s stock price over the past year highlights the need for a strategic response to regain investor confidence and market stability. For deeper insights and additional financial metrics, including 12 more exclusive ProTips, visit InvestingPro.
In other recent news, Evolent Health reported its fourth-quarter results, which did not meet analyst expectations. The company posted an adjusted earnings per share of -$0.02, missing the consensus estimate of $0.07. Revenue for the quarter was $646.5 million, falling short of the projected $652.2 million, though it marked a 16.3% year-over-year increase. For the full year 2024, Evolent achieved a revenue of $2.55 billion, a 30.1% growth over the previous year. However, the company’s 2025 revenue forecast of $2.06 billion to $2.11 billion is below the $2.42 billion anticipated by analysts.
Piper Sandler adjusted its price target for Evolent Health to $16 from $17 while maintaining an Overweight rating, following the company’s fourth-quarter earnings report. The firm noted that despite the earnings falling at the lower end of guidance, the results were better than expected. Additionally, Evolent Health’s strong bookings and full retention of top customers, accounting for 90% of its revenue, were highlighted as positive indicators. Citizens JMP also updated its outlook, raising the price target to $13 from $12 and reaffirming a Market Outperform rating. The firm’s analyst expressed confidence in Evolent Health’s management and its strategy to shield the business from external challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.